Leukemia, Myeloid: Clinical Trials

4,666 trials for Leukemia, Myeloid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2138 completed, 675 terminated, 621 recruiting, 512 unknown. 2041 Phase 2, 1746 Phase 1, 459 Phase 3, 333 Not applicable, 84 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 22041Completed 956, Terminated 315, Recruiting 245, Unknown 198, Active not recruiting 142, Withdrawn 90, Not yet recruiting 77, Enrolling by invitation 9, Suspended 9
Phase 11746Completed 780, Terminated 334, Recruiting 249, Unknown 129, Active not recruiting 105, Withdrawn 84, Not yet recruiting 44, Suspended 18, Enrolling by invitation 3
Phase 3459Completed 220, Unknown 73, Terminated 54, Recruiting 50, Active not recruiting 28, Not yet recruiting 19, Withdrawn 8, Enrolling by invitation 6, Suspended 1
Not applicable333Completed 141, Recruiting 54, Unknown 47, Terminated 39, Not yet recruiting 25, Active not recruiting 16, Withdrawn 10, Enrolling by invitation 1
Phase 484Completed 41, Unknown 23, Recruiting 7, Terminated 6, Not yet recruiting 3, Active not recruiting 2, Withdrawn 2
Early Phase 159Completed 16, Recruiting 13, Unknown 12, Not yet recruiting 8, Terminated 5, Active not recruiting 3, Withdrawn 2

Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1Not yet recruitingGerman Cancer Research Center122028-01-012025-03-14
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center582027-12-012026-08-25
Universal 4SCAR7U Targeting CD7-positive Malignancies
Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
Universal CAR-T Cells Targeting AML
CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells - Acute Myeloid Leukemia
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
GT737 Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Early Phase 1Not yet recruitingGrit Biotechnology362027-05-012026-09-11
A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AML
Dynamic BH3 Profiling, Venetoclax, Cytarabine - Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 2Not yet recruitingDana-Farber Cancer Institute402027-03-062026-11-19
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
Phase 1Not yet recruitingUniversity of Wisconsin, Madison272027-02-012026-11-02
S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation
S243249 600mg, S243249 400mg, S243249 450mg - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingServier802027-02-012026-11-16
Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
Levofloxacin, Usual Care - Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
Phase 2Not yet recruitingUniversity of Manitoba752027-02-012026-11-18
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation
Phase 1Not yet recruitingNorthside Hospital, Inc.322027-01-312026-10-16
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Leukemia, Myeloid, Chronic-Phase
Not yet recruitingNovartis Pharmaceuticals4002027-01-312026-11-10
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 2Not yet recruitingJonsson Comprehensive Cancer Center352027-01-302026-11-05
Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia
Phase 2Not yet recruitingNational Cancer Institute (NCI)1222027-01-152026-10-07
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia
Phase 2Not yet recruitingNational Cancer Institute (NCI)2442027-01-152026-10-20
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia
Phase 2RecruitingUma Borate702027-01-152026-11-09
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 2Not yet recruitingNational Cancer Institute (NCI)1842027-01-042026-10-01
Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)
Quizartinib, Midostaurin, Venetoclax - Acute Myeloid Leukemia
Phase 3Not yet recruitingUniversity Hospital, Toulouse12902027-01-042026-11-19
CD34+ Transplants for Myeloid Malignancies
Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Phase 2Not yet recruitingGuenther Koehne502027-01-012026-10-13
Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice
Bone marrow or peripheral blood withdrawal for test comparison - Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult
Not applicableNot yet recruitingGruppo Italiano Malattie EMatologiche dell'Adulto752027-01-012026-10-09

Showing 20 of 4666. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (3597)  ·  Myelodysplastic Syndromes (1254)  ·  Leukemia (1039)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (983)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (879)  ·  Leukemia, Myelomonocytic, Chronic (540)  ·  Lymphoma, Non-Hodgkin (476)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (475)  ·  Leukemia, Myeloid, Chronic-Phase (439)  ·  Multiple Myeloma (415)  ·  Hodgkin Disease (406)  ·  Myeloproliferative Disorders (406)  ·  Congenital Abnormalities (396)  ·  Recurrence (364)  ·  Blast Crisis (356)

Broader conditions

Hemic and Lymphatic Diseases (4665)  ·  Neoplasms by Histologic Type (4652)  ·  Hematologic Diseases (4609)  ·  Neoplasms (4499)  ·  Leukemia (3627)  ·  Bone Marrow Diseases (2408)  ·  Pathological Conditions, Signs and Symptoms (2033)  ·  Pathologic Processes (2016)  ·  Disease Attributes (1947)  ·  Chronic Disease (1705)  ·  Immune System Diseases (1291)  ·  Immunoproliferative Disorders (1231)  ·  Lymphatic Diseases (1215)  ·  Lymphoproliferative Disorders (1202)

Interventions

Cytarabine (638)  ·  Azacitidine (450)  ·  Cyclophosphamide (357)  ·  venetoclax (348)  ·  fludarabine phosphate (288)  ·  fludarabine (276)  ·  Busulfan (225)  ·  Decitabine (214)  ·  Idarubicin (176)  ·  Peripheral Blood Stem Cell Transplantation (176)  ·  Daunorubicin (173)  ·  Imatinib Mesylate (171)  ·  Mycophenolic Acid (171)  ·  Filgrastim (169)  ·  Whole-Body Irradiation (160)

Sponsors

M.D. Anderson Cancer Center (270)  ·  National Cancer Institute (NCI) (192)  ·  Fred Hutchinson Cancer Center (141)  ·  Novartis Pharmaceuticals (130)  ·  City of Hope Medical Center (72)  ·  Masonic Cancer Center, University of Minnesota (68)  ·  Memorial Sloan Kettering Cancer Center (67)  ·  The First Affiliated Hospital of Soochow University (53)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (50)  ·  Children's Oncology Group (49)  ·  Institute of Hematology & Blood Diseases Hospital, China (45)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (44)  ·  Washington University School of Medicine (43)  ·  Bristol-Myers Squibb (42)  ·  AbbVie (41)

Countries

United States (2693)  ·  China (532)  ·  France (486)  ·  Germany (405)  ·  Italy (353)  ·  Canada (306)  ·  Spain (278)  ·  United Kingdom (232)  ·  Australia (202)  ·  South Korea (180)  ·  Belgium (157)  ·  Netherlands (148)  ·  Japan (112)  ·  Poland (112)  ·  Israel (105)

Top investigators

Jorge Cortes, MD (25)  ·  Brenda Sandmaier (18)  ·  Farhad Ravandi-Kashani, MD (15)  ·  Jorge E Cortes, MD (12)  ·  Courtney DiNardo, MD (11)

Results publications

PMID 32499241, PMID 33394722, PMID 24383844, PMID 25527568, PMID 35235189, PMID 36064577, PMID 36184192, PMID 23524640, PMID 23620574, PMID 28835440, PMID 30885996, PMID 42013378, PMID 23065508, PMID 22965967, PMID 24923295, PMID 25361995, PMID 30062662, PMID 31171508, PMID 31375516, PMID 35829925, PMID 35982483, PMID 37267439, PMID 37341189, PMID 38507688, PMID 20705755, PMID 20965785, PMID 22825216, PMID 23841729, PMID 27400247, PMID 27400939, PMID 29702001, PMID 29859851, PMID 32786187, PMID 34699069, PMID 35007144, PMID 35790816, PMID 36815378, PMID 37093350, PMID 37553873, PMID 38295280, PMID 38429079, PMID 39133921, PMID 39368878, PMID 40073835, PMID 42085603, PMID 16775234, PMID 17151364, PMID 17715389, PMID 18824593, PMID 18997171

NIH funding

P30CA015704 (64), P30CA033572 (49), P30CA006973 (36), 2018 (29), 2023 (26), P30CA016672 (25), U10CA032102 (24), 2015 (23), P01CA018029 (23), U10CA031946 (23), P30CA043703 (22), U01CA070095 (21), 2014 (20), 2016 (19), 2025 (19)